Archive - The Sarcoma Letter

The Appointment

May 10, 2023 •

Regorafenib for Gastrointestinal Stromal Tumors

Third line treatment of GIST

Apr 26, 2023 •

Trends in FDA Approvals for Sarcoma

Where are we going?

Jul 8, 2023 •

Sarcoma Cellular Therapeutics Initiative

Making Something New

Dec 15, 2023 •

Avapritinib for PDGFRA D842V-Mutant GIST

Discussion of the NAVIGATOR Trial

May 5, 2023 •

History and Discovery

May 29, 2023 •

Second Opinions

Getting the best information

Jun 18, 2023 •

Clear Cell Sarcoma

Diagnosis and Treatment of Clear Cell Sarcoma

Apr 28, 2023 •

Grading in Soft Tissue Sarcomas

Why knowing grade is important for patients

Apr 7, 2023 •

Olaparib and Temozolomide

Later Line Treatment of Uterine LMS

Aug 14, 2023 •

Later Line therapies for patients with GIST

Gastrointestinal Stromal Tumors: when FDA approved treatments run out

Apr 15, 2023 •

Reflections on ASCO 2023

The need for more Randomized Controlled Trials

Jun 6, 2023 •

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts